Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Pheochromocytoma Overview | 6 | 1 |
| Therapeutics Development | 7 | 2 |
| Pipeline Products for Pheochromocytoma Overview | 7 | 1 |
| Pipeline Products for Pheochromocytoma Comparative Analysis | 8 | 1 |
| Pheochromocytoma Therapeutics under Development by Companies | 9 | 1 |
| Pheochromocytoma Therapeutics under Investigation by Universities/Institutes | 10 | 1 |
| Pheochromocytoma Pipeline Products Glance | 11 | 2 |
| Clinical Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Pheochromocytoma Products under Development by Companies | 13 | 1 |
| Pheochromocytoma Products under Investigation by Universities/Institutes | 14 | 1 |
| Pheochromocytoma Companies Involved in Therapeutics Development | 15 | 5 |
| Exelixis, Inc. | 15 | 1 |
| MediaPharma s.r.l. | 16 | 1 |
| Pfizer Inc. | 17 | 1 |
| Progenics Pharmaceuticals, Inc. | 18 | 1 |
| Valeant Pharmaceuticals International, Inc. | 19 | 1 |
| Pheochromocytoma Therapeutics Assessment | 20 | 8 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Target | 21 | 2 |
| Assessment by Mechanism of Action | 23 | 2 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 1 |
| Drug Profiles | 28 | 31 |
| cabozantinib s-malate Drug Profile | 28 | 18 |
| iobenguane sulfate I 131 Drug Profile | 46 | 3 |
| LMP-400 Drug Profile | 49 | 2 |
| metyrosine Drug Profile | 51 | 1 |
| MPBF-001 Drug Profile | 52 | 1 |
| S-43126 Drug Profile | 53 | 1 |
| sunitinib malate Drug Profile | 54 | 5 |
| Pheochromocytoma Dormant Projects | 59 | 1 |
| Pheochromocytoma Product Development Milestones | 60 | 5 |
| Featured News &Press Releases | 60 | 1 |
| Dec 03, 2015: Progenics Pharmaceuticals Achieves Target Enrollment in its Phase 2b Pivotal Trial of Azedra | 60 | 1 |
| Oct 12, 2015: Phase 2 Dosimetry Data for Progenics' AZEDRA Presented at EANM Congress 2015 | 60 | 1 |
| Jul 28, 2015: Progenics Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma | 61 | 1 |
| Mar 02, 2015: Progenics Pharmaceuticals Announces Presentation at ENDO 2015 | 61 | 1 |
| Jan 23, 2015: Progenics Pharmaceuticals Relaunches Pivotal Trial of AZEDRA in Pheochromocytoma | 61 | 1 |
| Sep 22, 2014: Progenics Pharmaceuticals Presents Long Term Follow-Up of Pivotal Phase 2 Trial of Azedra in Malignant Pheochromocytoma | 62 | 1 |
| Apr 01, 2014: Progenics Pharmaceuticals and Centre for Probe Development and Commercialization Announce Agreement to Manufacture Targeted Radiotherapeutic Candidate for Ultra-Orphan Indications | 63 | 1 |
| Nov 25, 2013: Progenics Pharmaceuticals Relaunching Registrational Trial of Azedra to Treat Pheochromocytomas | 63 | 2 |
| Appendix | 65 | 2 |
| Methodology | 65 | 1 |
| Coverage | 65 | 1 |
| Secondary Research | 65 | 1 |
| Primary Research | 65 | 1 |
| Expert Panel Validation | 65 | 1 |
| Contact Us | 65 | 1 |
| Disclaimer | 66 | 1 |
